Clinical Trials
11 trialsNCT07227311 2026-05-26
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT04508790 2026-05-04
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 2 Recruiting
NCT07523737 2026-04-15
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Recruiting
NCT05922501 2026-01-14
ISABELA
Massachusetts General Hospital
Phase 2 Recruiting
NCT07312188 2025-12-31
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 2 Recruiting
NCT05789303 2025-12-22
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Phase 2 Recruiting
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT07018050 2025-09-22
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05208307 2025-09-02
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Phase 2 Recruiting
NCT06342466 2024-12-30
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Phase 2 Recruiting
NCT05348213 2024-10-23
R-ICE+X
Ruijin Hospital
Phase 2 Recruiting